MASS COMM: Elective angioplasty can be performed in hospital with or without emergency surgical support.

Increasingly, the frequent performances of elective angioplasties are in hospitals that do not have a cardiac surgery team. The occurrence for the need of emergency surgery varies from 0.1 to 0.4% in the contemporary age. There is an ongoing debate on health policy about whether to perform elective coronary angioplasty at hospitals without cardiac surgery support. 

The main objective of MASS COMM was to compare safety and long-term outcomes among community hospitals with cardiac surgery and hospitals without cardiac surgery support in patients with ischemic heart disease treated with elective percutaneous coronary intervention. MASS COMM was a prospective, multicenter, randomized trial that found no differences in thirty day elective angioplasties performed in hospitals, with or without the support of cardiac surgery. Patients did not show different rates (MACE). Up to twelve months follow-up there was no difference in all-cause mortality, repeat revascularization or stroke

Read article

alice_jacobs_acc2013_presentacion
Alice Jacobs
2013-03-11

Original title: A Randomized Trial to Compare Percutaneous Coronary Intervention between Massachusetts Hospitals With Cardiac Surgery On-Site and Community Hospitals Without Cardiac Surgery On-Site ( MASS COMM ).

More articles by this author

PARTNER cohort A at three years, the benefit continues

The PARTNER Cohort A randomized 699 elderly patients, (mean age 84.1), with severe aortic stenosis for TAVI or conventional surgery in 26 centers. The...

ASTRONAUT: Aliskiren failed to show benefits in patients with acute heart failure

Hospitalization for heart failure, (HF), represents a major health problem with high rates of death or early readmission after discharge. The aim of this...

RELAX Study: Phosphodieserase-5 inhibitors showed no benefit in heart failure with preserved ventricular function.

Phosphodieserase-5 enzyme is activated in heart failure and can limit the beneficial effects of nitric oxide, (NO), in the vasculature, kidney and myocardium. The...

STOP-HF: The use of B-type natriuretic peptide (BNP) for screening high-risk population decreases the prevalence of heart failure

B-type natriuretic peptide (BNP) can be a reliable marker for the diagnosis of heart failure (HF). This study aimed to assess whether the use...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....